Sign in
Taking people in United StatesPhase 4

Lumateperone for Depression in Bipolar Disorder, With Weight and Brain Aging Measured

Tests lumateperone for mood symptoms in adults with bipolar depression and overweight.

Key facts

Who runs it
Massachusetts General Hospital
Where
Boston, United StatesSee the site
Trial code
Registry title
The Effects of Lumateperone on Obesity and Physiologic Aging and Their Association With Antidepressant Response in Bipolar Depression
Status
Recruiting
Phase
Phase 4
People taking part
25 people, planned
Started
9 Sept 2026
Expected to end
31 Jul 2028
Type of study
Interventional
Treatments tested
  • Lumateperone 42 mg
Record updated
11 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 65 with Bipolar I Disorder in a depressed phase and a BMI over 30. It tests lumateperone for about 6 weeks.

Age
18 to 65 years
Sex
All sexes can join.
Disease stage
Bipolar I Disorder, depressed phase, without psychosis. The current episode has lasted at least 4 weeks but not longer than 12 months. Depression score above 20 on the MADRS scale.
Earlier treatment
People with current or past treatment with lumateperone cannot join. People currently taking strong or moderate CYP3A4 inhibitors or inducers cannot join.
Biomarker or test result
BMI above 30.

Main reasons for not taking part

  • Schizophrenia, schizoaffective disorder, or significant mood-incongruent psychotic symptoms
  • Young Mania Rating Scale score above 12, or rapid cycling
  • Active substance use disorder within the past month
  • Significant risk of suicide, self-harm or harm to others
  • Pregnancy, or unwillingness to use birth control for women who can have children

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Aged 18 to 65 years
  • Meets DSM-V criteria for Bipolar I Disorder -Depressed without psychosis as confirmed by a semi-structured clinical interview that includes the Mini International Neuropsychiatric Interview
  • Current episode at least 4 weeks in duration but not longer than 12 months
  • Depression score > 20 on the Montgomery Asberg Depression Rating Scale (MADRS)
  • BMI > 30
  • Capable of providing informed consent

Who cannot take part

  • Current or prior treatment with lumateperone
  • Current treatment with strong or moderate CYP3A4 inhibitors or CYP3A4 inducers
  • Meets DSM-V criteria for Schizophrenia, Schizoaffective disorder, or has significant mood-incongruent psychotic symptoms
  • Co-Morbid psychiatric illness, other than generalized anxiety and specific phobias, that in the opinion of the investigator is severe enough that it would likely interfere with the interpretation of changes in the subject's mood state
  • Meets DSM-V criteria for an active substance use disorder within the past month
  • Active medical condition that in the opinion of the investigator would contribute to the subject's depressed mood (e.g. hypothyroidism)
  • Moderate or severe hepatic impairment
  • History of seizure disorder
  • Significant cardiovascular or cerebrovascular disease that, in the opinion of the investigator, would increase study risk
  • Dementia-related psychosis
  • Known hypersensitivity or allergy to lumateperone or any of its components
  • Young Mania Rating Scale score >12
  • Meets DSM-V criteria for rapid cycling
  • Significant risk of suicide or self -harm as assessed by clinical interview and the Columbia Suicide Severity Rating Scale (C-SSRS)
  • Significant risk of harm to others as assessed by clinical interview
  • Pregnancy, or, in women of child-bearing potential, an unwillingness to use an accepted method of birth control for the duration of the study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • Massachusetts General HospitalBoston, United StatesContact: Michael E Henry, MDTaking people

About the trial

What the trial wants to find out

This research study examines how a medication called lumateperone may affect mood symptoms, and inflammation in adults with bipolar disorder over approximately 6 weeks. An MRI scan to calculate biological age of the brain will also be obtained at the start of the study.

The group in the trial

  • Lumateperone treatmentTreatment being tested

    Lumateperone treatment for Bipolar type I depression

    Treatment: Lumateperone 42 mg

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The Effects of Lumateperone on Obesity and Physiologic Aging and Their Correlation With Antidepressant Response in Bipolar Depression
Plain-language title
Lumateperone for Depression in Bipolar Disorder, With Weight and Brain Aging MeasuredGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07699445, who can take part
Record updated
11 September 2026